PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Until recently, systemic chemotherapy was the only option for treating bladder cancer and outcomes remained dismal. After a long gap of no progress for 40 years, immuno-therapy with checkpoint inhibitors (PDL1 and PD1) has revolutionized the treatment paradigm of bladder cancer, with five approved agents to treat platinum-refractory bladder cancer since the first approval of atezolizumab in May 2016. METHODS: This review summarizes the most recent data on approved checkpoint inhibitors currently used in management of advanced bladder cancer. Early- and late-phase trials of the five checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab) in advanced bladder cancer are reviewed in detail. This review also describes the potential application of PD1/PDL1 inhibitors in adjuvant and neoadjuvant settings and non-muscle-invasive bladder cancer, as well as with radiation in muscle-invasive bladder cancer treatment. The role of PDL1 and tumor-mutation burden and clinical considerations in choosing a particular immunotherapy are also discussed. RESULTS: The approved checkpoint inhibitors (PD1 and PDL1 inhibitors) have similar efficacy and safety profiles in metastatic platinum-refractory bladder cancer, but they vary in dose and frequency and cost burden. However, only pembrolizumab has shown superiority over standard chemotherapy in a randomized Phase III setting so far. In addition, in the first-line setting for cisplatin-ineligible patients, both pembrolizumab and atezolizumab are US Food and Drug Administration-approved and well tolerated. There is a lack of consensus on the utility of testing for PDL1 as a predictive biomarker, as patients with no PDL1 expression also derive some clinical benefit. Tumor-mutation burden is another predictive biomarker, but needs further validation. CONCLUSION: Immunotherapy has offered a glimmer of hope to patients with bladder cancer. The current landscape is rapidly evolving, with novel immunotherapy-combination trials to improve outcomes further and evaluate predictive biomarkers to help identify patients most likely to benefit from such therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, PD-L1-negative tumors can still occasionally respond to anti-PD-1 therapy, and high PD-L1 expression, although correlative, is by no means sufficient for generating a response following anti-PD-1 therapy, indicating that other factors are involved in determining response and nonresponse to ICIs (80)(81)(82).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Bladder tumors have the third-highest rate of somatic mutations and are highly antigenic.(16) Additionally, therapeutic agents can be placed in direct contact with the tumor through intravesical administration, allowing a high concentration of the agent to be delivered with limited systemic exposure.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“17–19 It is also possible to monitor treatment response through direct surveillance of the tumor and related cells and biomarkers.”
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“The presence of certain bacteria in human microbiota (eg, commensal Bifidobacterium and Akkermansia muciniphila) is associated with an active immunoresponse when they are present in patients being treated with immunocheckpoint inhibitors.(47,48) Absence of these activating microbiota may result in an ineffective respo…”
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 4×
“The IMvigor 210 clinical study was a Phase II, multicenter, open-label trial of atezolizumab with two cohorts and provided the evidence for the FDA-approval decisions.(19,32) Cohort 1 included advanced UC patients who were ineligible O nc oT ar ge ts a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .”
InfluentialPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · cited 2×
“4%).(26) Treatment-related AEs occurred in 60.”
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · cited 1×
“Future immunotherapy-based clinical trials should consider utilizing RECIST for exploratory response assessment to provide a standardized format for assessing atypical responses.(46) Duration of therapy At present, there are no guidelines to stop treatment if patients are deriving clinical benefit or have achieved a c…”
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279 · cited 1×
“Prior to the advent of PD1/PDL1 checkpoint inhibitors, systemic chemotherapy with cisplatin-based regimens was the standard of care, leading to median survival of around 1 year.(5,6) For patients with platinum-refractory disease, the median survival was only 6–9 months.”
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · cited 4×
“5980 Stenehjem et al for first-line treatment with cisplatin.(32) Cohort 2 included patients with disease progression or recurrence after platinum therapy (second-line treatment).”
Influentialon behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533 · cited 3×
“Bladder cancer has been known to be immunoresponsive since original reports by Morales et al on the activity of intravesical instillation of bacillus Calmette–Guérin (BCG) in NMIBC.”
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869 · cited 1×
“The efficacy of durvalumab was studied in a UC dose-expansion cohort in a large Phase I/II, multicenter, multicohort, open-label clinical trial (Study 1108).(38,39) In this cohort, 191 patients with locally advanced or metastatic UC were enrolled.”
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840 · cited 1×
“The efficacy of durvalumab was studied in a UC dose-expansion cohort in a large Phase I/II, multicenter, multicohort, open-label clinical trial (Study 1108).(38,39) In this cohort, 191 patients with locally advanced or metastatic UC were enrolled.”
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., Dreicer, R., Vogelzang, N., Sternberg, C. N., Bajorin, D. F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8433 · Cited by 705
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Sternberg, C. N., de Mulder, P. H. M., Schornagel, J. H., Théodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, F., Spina, M., van Groeningen, C. J., de Balincourt, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2638 · Cited by 628
Surveillance, Epidemiology, and End Results Program
National Cancer Institute (2020) · Definitions · doi:10.32388/5owtl5 · Cited by 626
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590 · cited 1×
“The JAVELIN Solid Tumor trial was the basis for demonstrating efficacy and safety to support the accelerated FDA approval.(41,42) This was an open-label, single-arm, multicenter study.”
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585 · cited 1×
“41,42 This was an open-label, single-arm, multicenter study.”
The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
Cookson, M. S., Herr, H. W., Zhang, Z.-F., Soloway, S., Sogani, P. C., & Fair, W. R. (1997) · Journal of Urology · doi:10.1097/00005392-199707000-00017 · Cited by 549 · cited 2×
“5974 Stenehjem et al recurrences.(2) Muscle-invasive UC of the bladder accounts for 20%–40% of cases, and the standard of care is radical cystectomy with or without neoadjuvant chemotherapy or concurrent chemoradiation as a bladder-sparing option.”
Dash, A., Galsky, M. D., Vickers, A. J., Serio, A. M., Koppie, T. M., Dalbagni, G., & Bochner, B. H. (2006) · Cancer · doi:10.1002/cncr.22031 · Cited by 435
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Chan, T. A., Wolchok, J. D., & Snyder, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508163 · Cited by 420
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
McCaffrey, J. A., Hilton, S., Mazumdar, M., Sadan, S., Kelly, W. K., Scher, H. I., & Bajorin, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1853 · Cited by 371
Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., Lunceford, J., Saraf, S., Perini, R. F., & O'Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 335
Self-citationLorusso, V, Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., Oliva, C., Pacini, M., & De Lena, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00030-6 · Cited by 286
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.937 · Cited by 269
Releasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 252
Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
Sweeney, C. J., Roth, B. J., Kabbinavar, F. F., Vaughn, D. J., Arning, M., Curiel, R. E., Obasaju, C. K., Wang, Y., Nicol, S. J., & Kaufman, D. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6699 · Cited by 244 · cited 1×
“The median OS of 13 months was considered a significant improvement over the typical median survival time of 6–9 months with chemotherapy in the second-line setting.(30) A post hoc exploratory analysis was conducted to correlate baseline PDL1 expression with clinical response.”
Releasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166 · cited 3×
“Inhibitory checkpoints, such as PD1 present on T-cells and its ligands PDL1 and PDL2 regulate T-cell behavior in differentiating self from cancerous cells or pathogens.(20) The binding of PDL1, expressed on some cancer cells and antigen-presenting cells, to PD1 on activated T cells results in suppression of an immunor…”
InfluentialPapamichael, D., Gallagher, C., Oliver, R. T. D., Johnson, P., & Waxman, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.106 · Cited by 118
Treatment of carcinoma in situ of the bladder with BCG
Morales, Á. (1980) · Cancer Immunology Immunotherapy · doi:10.1007/bf00199531 · Cited by 76 · cited 1×
“BCG is a live attenuated tuberculosis-related bacteria that stimulates an immunologic reaction inducing a proinflammatory cytokine and direct cell-to-cell cytotoxicity, and was the first immunotherapy approved for NMIBC by the FDA in 1990.(14,15) Bladder tumors have the third-highest rate of somatic mutations and are…”
Urothelial carcinoma management in elderly or unfit patients
Bellmunt, J., Mottet, N., & Santis, M. D. (2016) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2016.01.001 · Cited by 69
Adjuvant and Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Literature Review
Pectasides, D. G., Pectasides, M., & Nikolaou, M. (2005) · European Urology · doi:10.1016/j.eururo.2005.03.025 · Cited by 66 · cited 1×
“However, even after treatment, up to 50% patients develop recurrence and most patients die of metastatic disease within 3 years of diagnosis.(4) De novo metastatic disease is present at diagnosis in 4% of patients.”
(2000) · Time to knit · doi:10.1016/j.ypdi.2016.02.003 · Cited by 63
Moskowitz, C. H., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Radford, J. A., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1107.1107 · Cited by 53
Puzanov, I. J., Dummer, R., Schachter, J., Pavlick, A. C., Gonzalez, R. C., Ascierto, P. A., Margolin, K. A., Hamid, O., Agarwala, S. S., Carlino, M. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3012 · Cited by 24
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, H. T., Lee, S. H., & Heo, Y.-S. (2019) · Molecules · doi:10.3390/molecules24061190 · Cited by 233
Mechanisms of immune evasion in bladder cancer
Crispen, P. L., & Kusmartsev, S. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02443-4 · Cited by 220
Metadata
- Authors
- Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Gupta, Shilpa
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-09
- Volume
- Volume 11
- Pages
- 5973-5989
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC6157986
- OpenAlex
- W2890398072
- Cited by
- 144
- References
- 47
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 26 · 2023: 20 · 2022: 19 · 2021: 25 · 2020: 25 · 2019: 10 · 2018: 2
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- PD-1 inhibitors, PD-L1 inhibitors, bladder urothelial carcinoma, immune checkpoint inhibitors, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, adjuvant immunotherapy, neoadjuvant immunotherapy, non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, radiotherapy, tumor mutational burden, predictive biomarkers, combination immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.